首頁 > 市場調查報告書 > 醫療設備

眼科設備激光

市場調查報告書

商品編碼

1576950

眼科用雷射的全球市場:洞察，競爭情形，市場預測:2030年

Ophthalmic Lasers - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 2024年10月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

2023年全球眼科雷射市場規模達12.5億美元。預計到 2030 年，該市場將達到 17.8 億美元，2024 年至 2030 年的預測期間複合年增長率為 6.11%。青光眼、糖尿病視網膜病變、老年黃斑部病變（AMD）和白內障等眼科疾病盛行率的上升是眼科雷射市場的關鍵推動因素。此外，由於微創手術具有更快的恢復時間、降低併發症風險和減輕疼痛等優點，患者和醫療保健提供者都強烈偏好微創手術。此外，2024年至2030年，主要市場參與者將繼續投資研發以推出創新的眼科雷射、增加夥伴關係和協作以及產品的發布和批准。。

根據世界衛生組織 (WHO) (2023) 提供的最新數據和統計數據，全球至少有 22 億人出現近距離視力或遠視力喪失。其中，約有 10 億人仍未解決。在這群人中，遠視力障礙和失明的主要原因是白內障（影響9,400 萬人）、屈光不正（影響8,840 萬人）和老年黃斑部病變（影響800 萬人）（影響770 萬人）。老花眼是近距離視力障礙的主要原因，影響 8.26 億人。

因此，隨著糖尿病視網膜病變、青光眼和老年黃斑部病變等疾病發生率的增加，對有效、微創治療的需求不斷增長。眼科雷射提供精確且有針對性的治療，可以比傳統方法更有效地治療這些疾病。例如，雷射治療糖尿病視網膜病變和視網膜靜脈阻塞可以防止視力喪失並改善預後。飛秒雷射和 YAG 雷射等創新雷射技術的進步擴大了可治療疾病的範圍並提高了治療效果。

此外，全球範圍內不斷增加的產品開發活動進一步推動了整個眼科雷射市場的發展。例如，2024 年 1 月，領先的雷射醫療設備供應商 IRIDEX Corporation 在美國宣布推出採用 IRIDEX 532 和 IRIDEX 577 雷射器的下一代平台。這些先進的雷射專為治療視網膜疾病和青光眼而設計，並提供多種治療模式，包括連續波和 Iridex 專有的微脈衝技術。該平台還擁有直覺的觸控螢幕介面，提供對各種臨床控制和設置的訪問，提高了易用性和治療準確性。

因此，上述因素可能會在預測期內推動眼科雷射市場的發展。

然而，使用眼科雷射設備後發生感染的風險以及對產品審批的嚴格監管擔憂可能會阻礙眼科雷射的未來市場。

本報告提供全球眼科用雷射市場相關調查，提供市場概要，以及各產品類型，各用途，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

Alcon Inc.
IRIDEX Corporation
Alna-Medicalsystem AG & Co. KG
BAUSCH + LOMB INCORPORATED
Lumenis Be Ltd.
Abbott
NIDEK CO., LTD.
MERIDIAN AG
Johnson & Johnson Vision
LIGHTMED
ZEISS
Navilas Academy
Aeon Meditec
Quantel Medical
Lumibird Medical
Ziemer Ophthalmic Systems AG
Novartis AG
Lumenis
Canon Medical Systems
Optovue

第9章 KOL的見解

第10章計劃的方法

第11章關於DelveInsight

第12章免責聲明和諮詢方式

簡介目錄圖表

Product Code: DIMDCL0510

Ophthalmic Lasers Market by Product Type (Argon Blue-Green Laser, ND: Yag Laser, Femtosecond Lasers, Krypton Red Laser, and Others), Application (Glaucoma, Diabetic Retinopathy, Cataracts, and Others), End-User (Hospitals, Ambulatory Surgical Centers, Ophthalmic Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the surge in the prevalence of ophthalmic diseases such as glaucoma, diabetic retinopathy, and others, growing preference for minimally invasive procedures, and increase in product launches and approvals by key market players across the globe.

The global ophthalmic laser devices market was valued at USD 1.25 billion in 2023, growing at a CAGR of 6.11% during the forecast period from 2024 to 2030, to reach USD 1.78 billion by 2030. The rising prevalence of ophthalmic diseases such as glaucoma, diabetic retinopathy, age-related macular degeneration (AMD), and cataracts are the major drivers for the ophthalmic lasers market. Additionally, a strong preference among patients and healthcare providers for minimally invasive procedures due to their benefits, including shorter recovery times, reduced risk of complications, and less pain. Furthermore, key market players continuously investing in research and development to introduce innovative ophthalmic lasers, increased partnerships and collaborations, product launches and approvals are some of the key factors boosting the market for ophthalmic lasers, during the forecast period from 2024 to 2030.

Ophthalmic Lasers Market Dynamics:

According to the recent data and stats provided by the World Health Organization (2023), globally, at least 2.2 billion people experienced near or distance vision impairment. Of these, approximately 1 billion cases remained unaddressed. Among this group, the leading causes of distance vision impairment or blindness included cataracts, affecting 94 million people; refractive errors, impacting 88.4 million; age-related macular degeneration, which affected 8 million; glaucoma, with 7.7 million cases; and diabetic retinopathy, affected 3.9 million. Presbyopia was the primary condition causing near vision impairment, affecting 826 million people.

Thus, as the incidence of conditions like diabetic retinopathy, glaucoma, and age-related macular degeneration rises, there is a growing demand for effective, minimally invasive treatments. Ophthalmic lasers offer precise, targeted therapies that can manage these disorders more efficiently than traditional methods. For instance, laser treatments for diabetic retinopathy and retinal vein occlusions can prevent vision loss and improve outcomes. The advancement of laser technology, with innovations such as femtosecond and YAG lasers, expanded the range of treatable conditions and enhanced procedural efficacy, driving further adoption in clinical settings and hence driving the market growth of ophthalmic laser across the globe.

Additionally, the increase in product development activities across the globe is further boosting the overall market of ophthalmic lasers. For instance, in January 2024, IRIDEX Corporation, a leading provider of laser-based medical equipment, unveiled its next-generation platform featuring the IRIDEX 532 and IRIDEX 577 lasers in the United States. These advanced lasers were designed for the treatment of retinal diseases and glaucoma, offering a range of treatment modes, including continuous-wave and IRIDEX's exclusive MicroPulse technology. The platform also boasts an intuitive touchscreen interface that provided the access to various clinical control features and settings, enhancing ease of use and precision in treatment.

Thus, the factors mentioned above are likely to boost the market of ophthalmic lasers during the forecasted period.

However, the risk of developing infection after the use of an ophthalmic laser device and stringent regulatory concerns for product approval may hinder the future market of ophthalmic lasers.

Ophthalmic Lasers Market Segment Analysis:

In the product type segment of the ophthalmic lasers market, femtosecond lasers is projected to hold a considerable market share in 2023. Femtosecond lasers can significantly boost the ophthalmic laser market through their advanced capabilities and the benefits they offer over traditional methods. These lasers operate at incredibly short pulse durations-femtoseconds (one quadrillionth of a second)-allowing for precise and controlled tissue disruption with minimal thermal damage. This precision are particularly advantageous in delicate eye surgeries, such as cataract surgery, where femtosecond lasers are used to perform tasks like corneal incision, lens fragmentation, and capsulotomy with high accuracy. By enhancing surgical outcomes and reducing complications, femtosecond lasers contribute to better patient experiences and quicker recoveries, which in turn increases their adoption among both surgeons and patients. The technology also allows for customized treatments, as surgeons can tailor the laser's parameters to each patient's specific anatomy and condition, further improving efficacy and safety. As a result, femtosecond lasers drive market growth by expanding the range of treatable conditions, enhancing procedural success rates, and encouraging investment in advanced ophthalmic technologies. This growth is further supported by ongoing advancements in laser technology and increasing patient demand for minimally invasive, precise, and effective treatment options.

Additionally, the increasing product approval across the globe are further propelling the market of the segment. For instance, In April 2023, Johnson & Johnson Vision, a global leader in eye health and part of Johnson & Johnson MedTech received U.S Food and Drug Administration FDA 510(k) approval on their ELITA Femtosecond Laser.

Therefore, owing to the above-mentioned factors, the femtosecond lasers category is expected to generate considerable revenue thereby pushing the overall growth of the global ophthalmic lasers market during the forecast period.

North America is expected to dominate the overall Ophthalmic Lasers market:

Among all the regions, North America is expected to hold the largest share in the global ophthalmic lasers market in 2023. The ophthalmic lasers market in North America is witnessing growth due to several factors like rising incidence of eye disorders like diabetic retinopathy and glaucoma across the region. Additionally, the market is benefited from the presence of prominent industry players and ongoing product development initiatives, including new launches and regulatory approvals. These factors collectively contribute to the expansion of the ophthalmic lasers market in North America, catering to the increasing demand for advanced treatments and technologies in eye care.

According to the data provided by the Centers for Disease Control and Prevention (CDC) (2023), in 2021 it was estimated that in the United States, around 9.6 million people with diabetes, or 2.6%, have diabetic retinopathy (DR), and 1.84 million, or 5.1% of those with diabetes, had vision-threatening diabetic retinopathy (VTDR). Among people over the age of 40 years with diabetes, approximately 1 in 4 had diabetic retinopathy. The prevalence of DR is highest (28.4%) in the 65-79 age group and lowest (13.0%) in those under 25. Overall, there were 8.94 million cases of diabetic retinopathy and 1.71 million cases of vision-threatening diabetic retinopathy among people aged 40 and above. Thus, the increasing prevalence of diabetic retinopathy (DR) in North America, is driving demand for ophthalmic lasers.

Furthermore, recent merger, acquisitions, and approvals among key market players in the region further propels the market across the region. For example, in September 2023, MERIDIAN AG got the approval from the U.S. Food and Drug Administration (FDA) for their innovative Merilas product family which was developed by MERIDIAN AG for the treatment of retinal disorder and glaucoma. Therefore, increasing product approvals, and launches of the product along with the presence of key players, among others is expected to boost the growth of the ophthalmic lasers market in the North American region during the forecast period from 2024 to 2030.

Ophthalmic Lasers Market Key Players:

Some of the key market players operating in the ophthalmic lasers market include Alcon Inc., IRIDEX Corporation, Alna-Medicalsystem AG & Co. KG, BAUSCH + LOMB INCORPORATED, Lumenis Be Ltd., Abbott, NIDEK CO., LTD, MERIDIAN AG, Johnson & Johnson Vision, LIGHTMED, ZEISS, Navilas Academy, Aeon Meditec, Quantel Medical, Lumibird Medical, Ziemer Ophthalmic Systems AG, Novartis, Lumenis, Canon Medical Systems, Optovue, and others.

Recent Developmental Activities in the Ophthalmic Lasers Market:

In January 2024, MERIDIAN AG received the U.S. Food and Drug Administration (FDA) approval for their MR Q series, this product provided a high-quality and inventive healthcare solution that required the needs of patients and physicians around the world.
In March 2021, IRIDEX Corporation, announced a collaboration with Topcon Corporation a Japanese manufacturer and distributor of the eye care business to expand their market of ophthalmic lasers in Asia-Pacific.

Key Takeaways From the Ophthalmic Lasers Market Report Study:

Market size analysis for current ophthalmic lasers size (2023), and market forecast for 6 years (2024 to 2030)
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the ophthalmic lasers market.
Various opportunities available for the other competitors in the ophthalmic lasers market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current ophthalmic lasers market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for ophthalmic lasers market growth in the coming future?

Target Audience who can be Benefited From This Ophthalmic Lasers Market Report Study:

Ophthalmic lasers product providers
Research organizations and consulting companies
Ophthalmic lasers -related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in ophthalmic lasers
Various end-users who want to know more about the ophthalmic lasers market and the latest technological developments in the ophthalmic lasers market.

Frequently Asked Questions for the Ophthalmic Lasers Market:

1. What are ophthalmic lasers?

An ophthalmic laser is a medical device used in eye care to perform precise and controlled procedures on the eye. It utilizes focused light beams to treat various eye conditions, including cataracts, glaucoma, and retinal disorders, by either cutting, reshaping, or stimulating tissues with minimal invasiveness.

2. What is the market for ophthalmic lasers?

The global ophthalmic laser devices market was valued at USD 1.25 billion in 2023, growing at a CAGR of 6.11% during the forecast period from 2024 to 2030, to reach USD 1.78 billion by 2030.

3. What are the drivers for the ophthalmic lasers market?

The rising prevalence of ophthalmic diseases such as glaucoma, diabetic retinopathy, age-related macular degeneration (AMD), and cataracts is a major driver of the ophthalmic laser market. Additionally, a strong preference among patients and healthcare providers for minimally invasive procedures due to their benefits, including shorter recovery times, reduced risk of complications, and less pain. Further, key market players continuously investing in research and development to introduce innovative ophthalmic lasers, increased partnerships and collaborations, product launches and approvals ensures that market remains dynamic and innovative, during the forecast period from 2024 to 2030.

4. Who are the key players operating in the ophthalmic lasers market?

Some of the key market players operating in the ophthalmic lasers market include Alcon Inc., IRIDEX Corporation, Alna-Medicalsystem AG & Co. KG, BAUSCH + LOMB INCORPORATED, Lumenis Be Ltd., Abbott, NIDEK CO., LTD, MERIDIAN AG, Johnson & Johnson Vision, LIGHTMED, ZEISS, Navilas Academy, Aeon Meditec, Quantel Medical, Lumibird Medical, Ziemer Ophthalmic Systems AG, Novartis, Lumenis, Canon Medical Systems, Optovue, and others.

5. Which region has the highest share in the ophthalmic lasers market?

North America is expected to hold the largest share in the global ophthalmic lasers market in 2023. This can be attributed to the rising incidence of eye disorders such as diabetic retinopathy and glaucoma across the region. Additionally, the market is benefited from the presence of prominent industry players and ongoing product development initiatives, including new launches and regulatory approvals. These factors collectively contribute to the expansion of the ophthalmic lasers market in North America, catering to the increasing demand for advanced treatments and technologies in eye care.

1. Ophthalmic Lasers Market Report Introduction

1.1. Scope of the Study
1.2. Market Segmentation
1.3. Market Assumption

2. Ophthalmic Lasers Market Executive Summary

2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

4.1. The United States
4.2. Europe
4.3. Japan
4.4. China

5. Ophthalmic Lasers Market Key Factors Analysis

5.1. Ophthalmic Lasers Market Drivers
- 5.1.1. Growing prevalence of ophthalmic diseases such as glaucoma, diabetic retinopathy, and others
- 5.1.2. Growing preference for minimally invasive procedures
- 5.1.3. Increase in product launches and approvals by key market players across the globe.
5.2. Ophthalmic Lasers Market Restraints and Challenges
- 5.2.1. Risk of developing infection after the use of ophthalmic lasers
- 5.2.2. Stringent regulatory concerns for product approval
5.3. Ophthalmic Lasers Market Opportunities
- 5.3.1. Integration of artificial intelligence in the field of ophthalmology lasers

6. Ophthalmic Lasers Market Porter's Five Forces Analysis

6.1. Bargaining Power of Suppliers
6.2. Bargaining Power of Consumers
6.3. Threat of New Entrants
6.4. Threat of Substitutes
6.5. Competitive Rivalry

7. Ophthalmic Lasers Market Assessment

7.1. By Product Type
- 7.1.1. Argon blue-green laser
- 7.1.2. ND: YAG Laser
- 7.1.3. Femtosecond Lasers
- 7.1.4. Krypton Red lasers
- 7.1.5. Others
7.2. By Application
- 7.2.1. Glaucoma
- 7.2.2. Diabetic Retinopathy
- 7.2.3. Cataracts
- 7.2.4. Others
7.3. By End-User
- 7.3.1. Hospitals
- 7.3.2. Ophthalmic Clinics
- 7.3.3. Ambulatory Surgical Centers
- 7.3.4. Others
7.4. By Geography
- 7.4.1. North America
  - 7.4.1.1. United States Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.1.2. Canada Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.1.3. Mexico Ophthalmic Lasers Market Size in USD Million (2021-2030)
- 7.4.2. Europe
  - 7.4.2.1. France Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.2.2. Germany Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.2.3. United Kingdom Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.2.4. Italy Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.2.5. Spain Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.2.6. Rest of Europe Ophthalmic Lasers Market Size in USD Million (2021-2030)
- 7.4.3. Asia-Pacific
  - 7.4.3.1. China Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.3.2. Japan Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.3.3. India Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.3.4. Australia Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.3.5. South Korea Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.3.6. Rest of Asia-Pacific Ophthalmic Lasers Market Size in USD Million (2021-2030)
- 7.4.4. Rest of the World (RoW)
  - 7.4.4.1. Middle East Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.4.2. Africa Ophthalmic Lasers Market Size in USD Million (2021-2030)
  - 7.4.4.3. South America Ophthalmic Lasers Market Size in USD Million (2021-2030)

8. Ophthalmic Lasers Market Company and Product Profiles

8.1. Alcon Inc.
- 8.1.1. Company Overview
- 8.1.2. Company Snapshot
- 8.1.3. Financial Overview
- 8.1.4. Product Listing
- 8.1.5. Entropy
8.2. IRIDEX Corporation
- 8.2.1. Company Overview
- 8.2.2. Company Snapshot
- 8.2.3. Financial Overview
- 8.2.4. Product Listing
- 8.2.5. Entropy
8.3. Alna-Medicalsystem AG & Co. KG
- 8.3.1. Company Overview
- 8.3.2. Company Snapshot
- 8.3.3. Financial Overview
- 8.3.4. Product Listing
- 8.3.5. Entropy
8.4. BAUSCH + LOMB INCORPORATED
- 8.4.1. Company Overview
- 8.4.2. Company Snapshot
- 8.4.3. Financial Overview
- 8.4.4. Product Listing
- 8.4.5. Entropy
8.5. Lumenis Be Ltd.
- 8.5.1. Company Overview
- 8.5.2. Company Snapshot
- 8.5.3. Financial Overview
- 8.5.4. Product Listing
- 8.5.5. Entropy
8.6. Abbott
- 8.6.1. Company Overview
- 8.6.2. Company Snapshot
- 8.6.3. Financial Overview
- 8.6.4. Product Listing
- 8.6.5. Entropy
8.7. NIDEK CO., LTD.
- 8.7.1. Company Overview
- 8.7.2. Company Snapshot
- 8.7.3. Financial Overview
- 8.7.4. Product Listing
- 8.7.5. Entropy
8.8. MERIDIAN AG
- 8.8.1. Company Overview
- 8.8.2. Company Snapshot
- 8.8.3. Financial Overview
- 8.8.4. Product Listing
- 8.8.5. Entropy
8.9. Johnson & Johnson Vision
- 8.9.1. Company Overview
- 8.9.2. Company Snapshot
- 8.9.3. Financial Overview
- 8.9.4. Product Listing
- 8.9.5. Entropy
8.10. LIGHTMED
- 8.10.1. Company Overview
- 8.10.2. Company Snapshot
- 8.10.3. Financial Overview
- 8.10.4. Product Listing
- 8.10.5. Entropy
8.11. ZEISS
- 8.11.1. Company Overview
- 8.11.2. Company Snapshot
- 8.11.3. Financial Overview
- 8.11.4. Product Listing
- 8.11.5. Entropy
8.12. Navilas Academy
- 8.12.1. Company Overview
- 8.12.2. Company Snapshot
- 8.12.3. Financial Overview
- 8.12.4. Product Listing
- 8.12.5. Entropy
8.13. Aeon Meditec
- 8.13.1. Company Overview
- 8.13.2. Company Snapshot
- 8.13.3. Financial Overview
- 8.13.4. Product Listing
- 8.13.5. Entropy
8.14. Quantel Medical
- 8.14.1. Company Overview
- 8.14.2. Company Snapshot
- 8.14.3. Financial Overview
- 8.14.4. Product Listing
- 8.14.5. Entropy
8.15. Lumibird Medical
- 8.15.1. Company Overview
- 8.15.2. Company Snapshot
- 8.15.3. Financial Overview
- 8.15.4. Product Listing
- 8.15.5. Entropy
8.16. Ziemer Ophthalmic Systems AG
- 8.16.1. Company Overview
- 8.16.2. Company Snapshot
- 8.16.3. Financial Overview
- 8.16.4. Product Listing
- 8.16.5. Entropy
8.17. Novartis AG
- 8.17.1. Company Overview
- 8.17.2. Company Snapshot
- 8.17.3. Financial Overview
- 8.17.4. Product Listing
- 8.17.5. Entropy
8.18. Lumenis
- 8.18.1. Company Overview
- 8.18.2. Company Snapshot
- 8.18.3. Financial Overview
- 8.18.4. Product Listing
- 8.18.5. Entropy
8.19. Canon Medical Systems
- 8.19.1. Company Overview
- 8.19.2. Company Snapshot
- 8.19.3. Financial Overview
- 8.19.4. Product Listing
- 8.19.5. Entropy
8.20. Optovue
- 8.20.1. Company Overview
- 8.20.2. Company Snapshot
- 8.20.3. Financial Overview
- 8.20.4. Product Listing
- 8.20.5. Entropy